Cargando…
The use of intravesical BCG in urothelial carcinoma of the bladder
The high recurrence and progression rates of non-muscle invasive bladder cancer (NMIBC) have led investigators to study the use of intravesical therapy in order to prevent them. Bacillus Calmette–Guérin (BCG) has been successfully used for this indication to treat NMIBC for more than four decades. B...
Autores principales: | Alhunaidi, Omar, Zlotta, Alexandre R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411413/ https://www.ncbi.nlm.nih.gov/pubmed/30915163 http://dx.doi.org/10.3332/ecancer.2019.905 |
Ejemplares similares
-
Intravesical therapy for urothelial carcinoma of the bladder
por: Manoharan, M.
Publicado: (2011) -
Systemic BCG‐osis following intravesical BCG instillation for bladder carcinoma
por: Liaw, Frank, et al.
Publicado: (2017) -
Urothelial Bladder Cancer Urinary Biomarkers
por: Noon, Aidan P, et al.
Publicado: (2014) -
Weekly intravesical bacillus Calmette-Guerin (BCG) alternating with epirubicin in Ta and T1 urothelial bladder cancer: An approach to decrease BCG toxicity
por: Ali-El-Dein, Bedeir, et al.
Publicado: (2013) -
Asymptomatic renal BCG granulomatosis: An unusual complication of intravesical BCG therapy for carcinoma urinary bladder
por: Bhat, Suresh, et al.
Publicado: (2015)